BACKGROUND: The epitope specificities and antiviral activities of class I HLA-restricted CD8(+) T cells, especially those induced during human immunodeficiency virus type 1 (HIV-1) primary infection, are important considerations in designing HIV-1 vaccines. Conserved epitopes may be more commonly and persistently recognized than variable epitopes, as they may be more likely to be present in infecting viruses. However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection. METHODS: We analyzed cytotoxic T-lymphocyte (CTL) responses toward predefined conserved and variable epitopes in 45 subjects during primary (n = 34) and/or chronic infection (n = 16). RESULTS: Conserved and variable CTL epitopes were recognized with similar probabilities, whereas conserved epitopes generally elicited subdominant responses during both primary and chronic infection. During primary infection, CTL responses against Gag versus responses against Env and variable epitopes tended to be associated with lower and higher viral loads, respectively. During chronic infection, Env-specific responses tended to be associated with lower CD4(+) cell counts. CONCLUSIONS: Subdominant CTL recognition of conserved HIV-1 epitopes commonly occurs from the primary through chronic stages of HIV-1 infection. These findings underscore the challenge in designing T cell-based vaccines that can induce immunodominant CTL responses to conserved HIV-1 regions.
BACKGROUND: The epitope specificities and antiviral activities of class I HLA-restricted CD8(+) T cells, especially those induced during humanimmunodeficiency virus type 1 (HIV-1) primary infection, are important considerations in designing HIV-1 vaccines. Conserved epitopes may be more commonly and persistently recognized than variable epitopes, as they may be more likely to be present in infecting viruses. However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection. METHODS: We analyzed cytotoxic T-lymphocyte (CTL) responses toward predefined conserved and variable epitopes in 45 subjects during primary (n = 34) and/or chronic infection (n = 16). RESULTS: Conserved and variable CTL epitopes were recognized with similar probabilities, whereas conserved epitopes generally elicited subdominant responses during both primary and chronic infection. During primary infection, CTL responses against Gag versus responses against Env and variable epitopes tended to be associated with lower and higher viral loads, respectively. During chronic infection, Env-specific responses tended to be associated with lower CD4(+) cell counts. CONCLUSIONS: Subdominant CTL recognition of conserved HIV-1 epitopes commonly occurs from the primary through chronic stages of HIV-1 infection. These findings underscore the challenge in designing T cell-based vaccines that can induce immunodominant CTL responses to conserved HIV-1 regions.
Authors: Mathias Lichterfeld; Xu G Yu; Daniel Cohen; Marylyn M Addo; Jessica Malenfant; Beth Perkins; Eunice Pae; Mary N Johnston; Daryld Strick; Todd M Allen; Eric S Rosenberg; Bette Korber; Bruce D Walker; Marcus Altfeld Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Florian Bihl; Nicole Frahm; Loriana Di Giammarino; John Sidney; Mina John; Karina Yusim; Tonia Woodberry; Kaori Sango; Hannah S Hewitt; Leah Henry; Caitlyn H Linde; John V Chisholm; Tauheed M Zaman; Eunice Pae; Simon Mallal; Bruce D Walker; Alessandro Sette; Bette T Korber; David Heckerman; Christian Brander Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422
Authors: Nicole Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander Journal: J Virol Date: 2004-03 Impact factor: 5.103
Authors: Marcus Altfeld; Elizabeth T Kalife; Ying Qi; Hendrik Streeck; Mathias Lichterfeld; Mary N Johnston; Nicole Burgett; Martha E Swartz; Amy Yang; Galit Alter; Xu G Yu; Angela Meier; Juergen K Rockstroh; Todd M Allen; Heiko Jessen; Eric S Rosenberg; Mary Carrington; Bruce D Walker Journal: PLoS Med Date: 2006-10 Impact factor: 11.069
Authors: Matthew S Sutton; Amy Ellis-Connell; Ryan V Moriarty; Alexis J Balgeman; Dane Gellerup; Gabrielle Barry; Andrea M Weiler; Thomas C Friedrich; Shelby L O'Connor Journal: J Virol Date: 2018-10-12 Impact factor: 5.103
Authors: Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot Journal: Vaccine Date: 2012-10-24 Impact factor: 3.641
Authors: Catherine A Brennan; F Javier Ibarrondo; Catherine A Sugar; Mary Ann Hausner; Roger Shih; Hwee L Ng; Roger Detels; Joseph B Margolick; Charles R Rinaldo; John Phair; Lisa P Jacobson; Otto O Yang; Beth D Jamieson Journal: J Virol Date: 2012-07-18 Impact factor: 5.103
Authors: Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker Journal: J Immunol Date: 2011-05-16 Impact factor: 5.422
Authors: Liguo Niu; James M Termini; Saravana K Kanagavelu; Sachin Gupta; Morgane M Rolland; Viraj Kulkarni; George N Pavlakis; Barbara K Felber; James I Mullins; Margaret A Fischl; Geoffrey W Stone Journal: Vaccine Date: 2011-01-15 Impact factor: 3.641
Authors: Pratima Kunwar; Natalie Hawkins; Warren L Dinges; Yi Liu; Erin E Gabriel; David A Swan; Claire E Stevens; Janine Maenza; Ann C Collier; James I Mullins; Tomer Hertz; Xuesong Yu; Helen Horton Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240
Authors: Eung-Jun Im; Jessie P Hong; Yaowaluck Roshorm; Anne Bridgeman; Sven Létourneau; Peter Liljeström; Mary Jane Potash; David J Volsky; Andrew J McMichael; Tomáš Hanke Journal: PLoS Pathog Date: 2011-05-19 Impact factor: 6.823
Authors: Stephen A Migueles; Daniel Mendoza; Matthew G Zimmerman; Kelly M Martins; Sushila A Toulmin; Elizabeth P Kelly; Bennett A Peterson; Sarah A Johnson; Eric Galson; Kate O Poropatich; Andy Patamawenu; Hiromi Imamichi; Alexander Ober; Catherine A Rehm; Sara Jones; Claire W Hallahan; Dean A Follmann; Mark Connors Journal: EBioMedicine Date: 2014-12-22 Impact factor: 8.143